LIFERIVER(SH:688317)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥810,004,473.78, representing a year-over-year increase of 23.43%[5] - The net profit attributable to shareholders decreased by 12.90% to ¥275,435,800.66 compared to the same period last year[5] - Basic and diluted earnings per share were both ¥1.41, reflecting a decrease of 20.34% year-over-year[6] - Operating profit for Q1 2022 was ¥324,239,329.48, compared to ¥375,456,296.63 in Q1 2021, reflecting a decrease of 13.6%[16] - Net profit for Q1 2022 was ¥275,435,800.66, down 13.0% from ¥316,215,504.78 in Q1 2021[16] - Total comprehensive income for Q1 2022 was CNY 267,248,470.93, a decrease from CNY 278,047,895.24 in Q1 2021[17] Cash Flow - The net cash flow from operating activities increased by 53.78% to ¥275,709,142.52, primarily due to increased sales and cash collection[7] - Net cash flow from operating activities for Q1 2022 was CNY 275,709,142.52, up from CNY 179,287,670.20 in Q1 2021, representing a growth of 53.5%[20] - The company experienced a net cash outflow from investing activities of CNY -43,788,254.52 in Q1 2022, compared to a larger outflow of CNY -244,979,043.85 in Q1 2021[21] - Cash flow from financing activities in Q1 2022 resulted in a net inflow of CNY 1,948,049,340.89, significantly higher than the previous year[21] - The company received CNY 332,656,747.44 from investment recoveries in Q1 2022, with no such cash inflow reported in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,549,113,091.56, an increase of 6.92% from the end of the previous year[6] - Current assets totaled ¥3,876,172,287.97, up from ¥3,552,844,091.97 at the end of 2021, indicating a growth of 9.1%[12] - Total liabilities increased to ¥454,455,652.71 from ¥427,270,685.63, marking a rise of 6.0%[14] - Cash and cash equivalents rose to ¥3,164,464,365.60, compared to ¥2,935,924,970.17 at the end of 2021, an increase of 7.8%[12] - The company’s equity attributable to shareholders increased to ¥4,094,657,438.85 from ¥3,827,408,967.91, reflecting a growth of 7.0%[14] Research and Development - Research and development expenses totaled ¥11,128,219.98, which is a decrease of 28.58% year-over-year, accounting for 1.37% of operating revenue[6] - Research and development expenses for Q1 2022 were ¥11,128,219.98, down 28.5% from ¥15,580,686.48 in Q1 2021[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,723[9] - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., held 33.37% of the shares[9] Other Information - The company did not report any significant new product developments or market expansion strategies during this quarter[11] - The company reported a financial income of ¥33,230,483.14 in Q1 2022, significantly higher than ¥3,126,810.98 in Q1 2021[16] - The company paid CNY 49,768,936.33 in taxes during Q1 2022, down from CNY 105,516,974.81 in Q1 2021, indicating a reduction of 52.8%[20] - The company reported a net loss in other comprehensive income of CNY -8,187,329.73 for Q1 2022, compared to a loss of CNY -38,167,609.54 in Q1 2021[17]